01.03.2011 | Correspondence
Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?
Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2011
Einloggen, um Zugang zu erhalten